Circulating tumor biomarkers in meningiomas reveal a signature of equilibrium between tumor growth and immune modulation

Erdogan Pekcan Erkan, Thomas Ströbel, Christian Dorfer, Markus Sonntagbauer, Andreas Weinhäusel, Nurten Saydam, Okay Saydam

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Meningiomas are primary central nervous system (CNS) tumors that originate from the arachnoid cells of the meninges. Recurrence occurs in higher grade meningiomas and a small subset of Grade I meningiomas with benign histology. Currently, there are no established circulating tumor markers which can be used for diagnostic and prognostic purposes in a non-invasive way for meningiomas. Here, we aimed to identify potential biomarkers of meningioma in patient sera. For this purpose, we collected preoperative (n = 30) serum samples from the meningioma patients classified as Grade I (n = 23), Grade II (n = 4), or Grade III (n = 3). We used a high-throughput, multiplex immunoassay cancer panel comprising of 92 cancer-related protein biomarkers to explore the serum protein profiles of meningioma patients. We detected 14 differentially expressed proteins in the sera of the Grade I meningioma patients in comparison to the age-and gender-matched control subjects (n = 12). Compared to the control group, Grade I meningioma patients showed increased serum levels of amphiregulin (AREG), CCL24, CD69, prolactin, EGF, HB-EGF, caspase-3, and decreased levels of VEGFD, TGF-α, E-Selectin, BAFF, IL-12, CCL9, and GH. For validation studies, we utilized an independent set of meningioma tumor tissue samples (Grade I, n = 20; Grade II, n = 10; Grade III, n = 6), and found that the expressions of amphiregulin and Caspase3 are significantly increased in all grades of meningiomas either at the transcriptional or protein level, respectively. In contrast, the gene expression of VEGF-D was significantly lower in Grade I meningioma tissue samples. Taken together, our study identifies a meningioma-specific protein signature in blood circulation of meningioma patients and highlights the importance of equilibrium between tumor-promoting factors and anti-tumor immunity.

Original languageEnglish (US)
Article number1031
JournalFrontiers in Oncology
Issue numberSEP
StatePublished - Sep 1 2019

Bibliographical note

Publisher Copyright:
© 2019 Erkan, Ströbel, Dorfer, Sonntagbauer, Weinhäusel, Saydam and Saydam.


  • Biomarker
  • CNS tumors
  • High-throughput immunoassay cancer panel
  • Meningioma
  • Proximity extension assay
  • Serum biomarker


Dive into the research topics of 'Circulating tumor biomarkers in meningiomas reveal a signature of equilibrium between tumor growth and immune modulation'. Together they form a unique fingerprint.

Cite this